{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:56:20Z","timestamp":1759146980735,"version":"3.38.0"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.msard.2025.106334","type":"journal-article","created":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T06:52:58Z","timestamp":1739083978000},"page":"106334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Central American and Caribbean consensus for the treatment of MS, NMOSD, and MOGAD"],"prefix":"10.1016","volume":"95","author":[{"given":"Deyanira A.","family":"Ramirez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Gracia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro J. Diaz","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla Monterrey","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awilda E.","family":"Candelario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romy","family":"Castro-Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anyeri I. de Pe\u00f1a","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amado","family":"Diaz de la Fe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R. Dondis","family":"Cama\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Octavio A. Duarte","family":"Sotelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis A. Garcia","family":"Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria M.A. Gramajo","family":"Juarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ericka Lopez","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander Parajeles","family":"Vindas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ligia I. Portillo","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicia E. Ramirez","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis C. Rodriguez","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biany Santos","family":"Pujols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah B. Vargas","family":"Santana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indhira Zabala","family":"Angeles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9232-0600","authenticated-orcid":false,"given":"Joaquin A.","family":"Pena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor M.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.msard.2025.106334_bib0001","first-page":"737","article-title":"LACTRIMS consensus document for the pharmacological treatment of multiple sclerosis and its clinical variants","volume":"55","author":"Abad","year":"2012","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.msard.2025.106334_bib0002","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0140-6736(02)68218-2","article-title":"On the ophthalmoscopic signs of spinal disease","author":"Albutt","year":"1870","journal-title":"Lancet."},{"key":"10.1016\/j.msard.2025.106334_bib0003","article-title":"Management of multiple sclerosis in the breastfeeding mother","volume":"2016","author":"Almas","year":"2016","journal-title":"Mult. Scler. Int."},{"issue":"3","key":"10.1016\/j.msard.2025.106334_bib0004","article-title":"Epidemiology of neuromyelitis optica in Latin America","volume":"3","author":"Alvarenga","year":"2017","journal-title":"Mult. Scler. J. Exp., Transl. Clin."},{"issue":"1","key":"10.1016\/j.msard.2025.106334_bib0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.46997\/revecuatneurol29100062","article-title":"Factores Cl\u00ednicos y Radiol\u00f3gicos Relacionados con la progresi\u00f3n de la discapacidad en esclerosis m\u00faltiple [Spanish]. Clinical and radiological factors related to the progression of disability In multiple sclerosis","volume":"29","author":"Arteaga Noriega","year":"2020","journal-title":"Rev. Ecuat. Neurol."},{"key":"10.1016\/j.msard.2025.106334_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103044","article-title":"A comparison of the effects of rituximab versus other immunotherapies for MOG-IgG-associated central nervous system demyelination: A meta-analysis","volume":"53","author":"Bai","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2025.106334_bib0007","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2025.106334_bib0008","first-page":"12","article-title":"Pregnancy management in multiple sclerosis and other demyelinating diseases","volume":"28","author":"Bove","year":"2022","journal-title":"Contin. (Minneapol., Minn.)"},{"issue":"3","key":"10.1016\/j.msard.2025.106334_bib0009","doi-asserted-by":"crossref","first-page":"256","DOI":"10.5603\/PJNNS.a2022.0047","article-title":"Highly active disease and access to disease-modifying treatments in patients with relapsing-remitting multiple sclerosis in Poland","volume":"56","author":"Brola","year":"2022","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.msard.2025.106334_bib0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","article-title":"E.U. paediatric MOG consortium consensus: part 5 - treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2025.106334_bib0011","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1177\/1352458516675751","article-title":"Discontinuation of disease-modifying therapies in multiple sclerosis\u2014Clinical outcome and prognostic factors","volume":"23","author":"Bsteh","year":"2017","journal-title":"Multi. Scler."},{"issue":"7","key":"10.1016\/j.msard.2025.106334_bib0012","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/14740338.2018.1483330","article-title":"Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis","volume":"17","author":"Buonomo","year":"2018","journal-title":"Expert Opin. Drug. Saf."},{"issue":"1","key":"10.1016\/j.msard.2025.106334_bib0013","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/1352458516638941","article-title":"The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis","volume":"23","author":"Cadavid","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106334_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102428","article-title":"Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice","volume":"45","author":"Carnero Contentti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106334_bib0015","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2025.106334_bib0016","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","article-title":"Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease","volume":"16","author":"Cobo-Calvo","year":"2019","journal-title":"J. Neuroinflammat."},{"issue":"9648","key":"10.1016\/j.msard.2025.106334_bib0017","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2025.106334_bib0018","article-title":"Prevalence of multiple sclerosis in Latin America and its relationship with European migration","author":"Correa","year":"2016","journal-title":"Mult. Scler. J. - Exp., Transl. Clin."},{"issue":"2","key":"10.1016\/j.msard.2025.106334_bib0019","article-title":"Multiple sclerosis epidemiology in Latin America: an updated survey","volume":"3","author":"Cristiano","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"7","key":"10.1016\/j.msard.2025.106334_bib0020","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1177\/1352458512462918","article-title":"The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review","volume":"19","author":"Cristiano","year":"2013","journal-title":"Mul. Scler."},{"issue":"3","key":"10.1016\/j.msard.2025.106334_bib0021","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1212\/WNL.0000000000001756","article-title":"Unraveling the neuroimaging predictors for motor dysfunction in long-standing multiple sclerosis","volume":"85","author":"Daams","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2025.106334_bib0022","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s13760-021-01712-3","article-title":"Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: A single-center Belgian cohort","volume":"122","author":"Dauby","year":"2022","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.msard.2025.106334_bib0023","first-page":"1033","article-title":"Myelite aigue compliquee de nevrite optique [French] acute myelitis complicated with optica neuritis","volume":"8","author":"Devic","year":"1894","journal-title":"Bull. Med. (Paris)"},{"key":"10.1016\/j.msard.2025.106334_bib0024","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.msard.2019.01.039","article-title":"Highly active multiple sclerosis: an update","volume":"30","author":"D\u00edaz","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2025.106334_bib0025","first-page":"637","article-title":"Central American and Caribbean consensus for the treatment of multiple sclerosis and therapeutic attitudes facing the COVID-19 Pandemic","volume":"3","author":"Diaz Jimenez","year":"2020","journal-title":"J. Curr. Med. Res. Opin."},{"issue":"2","key":"10.1016\/j.msard.2025.106334_bib0026","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1352458514546790","article-title":"Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study","volume":"21","author":"Ebrahimi","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106334_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102696","article-title":"Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review","volume":"48","author":"Elsbernd","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106334_bib0028","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/BF02224560","article-title":"Ueber das Zusammvonenvorkommen von Neuritis optica und myelitis subacuta [German]. On the co-occurrence of neuritis optica and subacute myelitis","volume":"10","author":"Erb","year":"1880","journal-title":"Arch. Psychiatr. Nervenkr."},{"issue":"2","key":"10.1016\/j.msard.2025.106334_bib0029","first-page":"134","article-title":"Mexican consensus for the use of immunoglobulin G as replacement and immunomodulation treatment","volume":"39","author":"Espinoza Rosales","year":"2018","journal-title":"Acta Pediatr. Mex."},{"issue":"1","key":"10.1016\/j.msard.2025.106334_bib0030","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1471-2377-13-180","article-title":"Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: A systematic literature review and regression analysis","volume":"13","author":"Fahrbach","year":"2013","journal-title":"BMC Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106334_bib0031","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40264-018-0782-8","article-title":"Managing risks with immune therapies in multiple sclerosis","volume":"42","author":"F\u00f6rster","year":"2019","journal-title":"Drug. Saf."},{"issue":"10","key":"10.1016\/j.msard.2025.106334_bib0032","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1177\/13524585221078825","article-title":"Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II","volume":"28","author":"G\u00e4rtner","year":"2022","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2025.106334_bib0033","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo -controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106334_bib0034","unstructured":"Glisson C. 2024. Neuromyelitis optica spectrum disorder (NMOSD): treatment and prognosis. Up to Date. retrived from: https:\/\/sso.uptodate.com\/contents\/neuromyelitis-optica-spectrum-disorder-nmosd-treatment-and-prognosis?search=neuromyelitis%20optica%20spectrum%20disorde (accessed 07-06-24)."},{"issue":"3","key":"10.1016\/j.msard.2025.106334_bib0035","first-page":"134","article-title":"Multiple sclerosis in Central American and Spanish caribbean region: should it be recognized as a public health problem","volume":"3","author":"Gracia","year":"2017","journal-title":"J. Epidem. Prev. Med."},{"issue":"1","key":"10.1016\/j.msard.2025.106334_bib0036","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3390\/neurolint14010023","article-title":"Neuromyelitis Optica spectrum Disorder in Central America and the Caribbean: A multinational clinical characterization study","volume":"14","author":"Gracia","year":"2022","journal-title":"Neurol. Int."},{"key":"10.1016\/j.msard.2025.106334_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fepid.2024.1368675","article-title":"Multiple sclerosis in Central America and Caribbean countries: frequency and clinical characterization of an emergent disease","volume":"4","author":"Gracia","year":"2024","journal-title":"Front. Epidemiol."},{"issue":"11","key":"10.1016\/j.msard.2025.106334_bib0038","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11910-017-0800-8","article-title":"Infections in patients receiving multiple sclerosis disease-modifying therapies","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"No.RR-3","key":"10.1016\/j.msard.2025.106334_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6803a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2019-20 influenza season","volume":"68","author":"Grohskopt","year":"2019","journal-title":"MMWR Recomm. Rep."},{"issue":"4","key":"10.1016\/j.msard.2025.106334_bib0040","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated Disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106334_bib0041","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.msard.2025.106334_bib0042","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.msard.2025.106334_bib0043","first-page":"1694","article-title":"Ocrelizumab in primary progressive and relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.msard.2025.106334_bib0044","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2015.1806","article-title":"Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses","volume":"72","author":"Hellwig","year":"2015","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106334_bib0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12883-023-03109-6","article-title":"Predictors of severity and outcome of multiple sclerosis relapses","volume":"23","author":"Hosny","year":"2023","journal-title":"BMC Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106334_bib0046","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuarg.2023.02.003","article-title":"Guia de practica clinica: tratamiento agudo de las enfermedades inflamatorio-desmielinizantes del sistema nervioso central [Spanish] acute treatment of inflammatory -demyelinating diseases of the SNC","volume":"15","author":"Hryb","year":"2018","journal-title":"Neurolog. Argentina"},{"issue":"5","key":"10.1016\/j.msard.2025.106334_bib0047","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/1352458518765656","article-title":"Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60","volume":"25","author":"Hua","year":"2019","journal-title":"Mult. Scler."},{"issue":"10 Suppl 6","key":"10.1016\/j.msard.2025.106334_bib0048","first-page":"S23","article-title":"Vaccinations recommended during pregnancy and breastfeeding","volume":"111","author":"Hubka","year":"2011","journal-title":"J. Am. Osteopath. Assoc."},{"issue":"9","key":"10.1016\/j.msard.2025.106334_bib0049","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1177\/1352458520925369","article-title":"Aggressive multiple sclerosis (1): towards a definition of the phenotype","volume":"26","author":"Iacobaeus","year":"2020","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2025.106334_bib0050","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammat."},{"issue":"5","key":"10.1016\/j.msard.2025.106334_bib0051","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/acn3.187","article-title":"Predictors of disability worsening in clinically isolated syndrome","volume":"2","author":"Jokubaitis","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106334_bib0052","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of Neuromyelitis Optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2025.106334_bib0053","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/jnnp-2016-313760","article-title":"Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: A propensity score-matched study","volume":"87","author":"Kister","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.msard.2025.106334_bib0054","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2025.106334_bib0055","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1474-4422(22)00426-4","article-title":"Family planning considerations in people with multiple sclerosis","volume":"22","author":"Krysko","year":"2023","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106334_bib109","first-page":"773","article-title":"Pregnancy and family planning in multiple sclerosis","volume":"25","author":"Langer-Gould","year":"2019","journal-title":"Continuum (Minneap)"},{"issue":"9451","key":"10.1016\/j.msard.2025.106334_bib0056","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.msard.2025.106334_bib0057","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3390\/ijms24020916","article-title":"Leukocyte telomere length predicts severe disability in relapsing-remitting multiple sclerosis and correlates with mitochondrial DNA copy number","volume":"24","author":"L\u00f3pez-Armas","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl 1","key":"10.1016\/j.msard.2025.106334_bib0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000367614","article-title":"New multiple sclerosis phenotypic classification","volume":"72","author":"Lublin","year":"2014","journal-title":"Eur. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106334_bib0059","first-page":"907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey","volume":"46","author":"Lublin","year":"1996","journal-title":"Natl. Mult. Scler. Soc. (USA) Advis. Committ. Clin. Trial. New Agent. Mult. Scler. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106334_bib0060","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/WCO.0000000000000813","article-title":"Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases","volume":"33","author":"Mader","year":"2020","journal-title":"Curr. Opin. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2025.106334_bib0061","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.msard.2014.07.003","article-title":"Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis","volume":"3","author":"Maghzi","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2025.106334_bib0062","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/08916934.2017.1373766","article-title":"Effects of immunomodulators on the response induced by vaccines against autoimmune diseases","volume":"50","author":"Marciani","year":"2017","journal-title":"Autoimmunity"},{"issue":"9","key":"10.1016\/j.msard.2025.106334_bib0063","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106334_bib0064","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1474-4422(05)70071-5","article-title":"Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis","volume":"4","author":"Miller","year":"2005","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106334_bib0065","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2025.106334_bib0066","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in primary progressive Multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106334_bib0067","unstructured":"National Multiple Sclerosis Society. 2024. Vaccinations with multiple sclerosis. retrieved from: https:\/\/www.nationalmssociety.org\/managing-ms\/living-with-ms\/diet-exercise-and-healthy-behaviors\/vaccination."},{"issue":"3","key":"10.1016\/j.msard.2025.106334_bib0068","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1212\/CPJ.0b013e318296f299","article-title":"Teriflunomide","volume":"3","author":"Oh","year":"2013","journal-title":"Neurol. Clin. Pract."},{"issue":"8","key":"10.1016\/j.msard.2025.106334_bib0069","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1111\/ene.15809","article-title":"European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: improving immunization strategies in the era of highly active immunotherapeutic drugs","volume":"30","author":"Otero-Romero","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106334_bib0070","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.nrl.2020.02.006","article-title":"Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement","volume":"36","author":"Otero-Romero","year":"2021","journal-title":"Neurolog\u00eda"},{"key":"10.1016\/j.msard.2025.106334_bib0071","first-page":"217","article-title":"Travel advice for the immunocompromised traveler: prophylaxis, vaccination, and other preventive measures","volume":"11","author":"Patel","year":"2015","journal-title":"Ther. Clin. Risk. Manag."},{"issue":"37","key":"10.1016\/j.msard.2025.106334_bib0072","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1016\/j.vaccine.2014.06.068","article-title":"Efficacy of vaccination against influenza in patients with multiple sclerosis: the role of concomitant therapies","volume":"32","author":"Pellegrino","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.msard.2025.106334_bib0073","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106334_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102483","article-title":"Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: a case-series","volume":"46","author":"Rigal","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106334_bib0075","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jns.2015.12.043","article-title":"Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis","volume":"361","author":"R\u00edo","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.msard.2025.106334_bib0076","doi-asserted-by":"crossref","first-page":"139","DOI":"10.31083\/j.jin2206139","article-title":"Neuromyelitis Optica Spectrum disorder: redefining an old disease. Present and future challenges","volume":"22","author":"Rivera","year":"2023","journal-title":"J. Integr. Neurosci."},{"key":"10.1016\/j.msard.2025.106334_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103083","article-title":"Status of the neuromyelitis optica spectrum disorder in Latin America","volume":"53","author":"Rivera","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106334_bib0078","article-title":"Access and barriers to MS care in Latin America","volume":"3","author":"Rivera","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"9","key":"10.1016\/j.msard.2025.106334_bib0079","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/brain\/awaa231","article-title":"Delay from treatment start to full effect of immunotherapies for multiple sclerosis","volume":"143","author":"Roos","year":"2020","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.msard.2025.106334_bib0080","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.msard.2014.01.003","article-title":"Cognitive performance profile in different phenotypes of MS with cognitive complaints","volume":"3","author":"Rosti-Otaj\u00e4rvi","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2025.106334_bib0081","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41582-019-0170-8","article-title":"Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis","volume":"15","author":"Rotstein","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"13","key":"10.1016\/j.msard.2025.106334_bib0082","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1177\/1352458514533397","article-title":"Early predictors of multiple sclerosis after a typical clinically isolated syndrome","volume":"20","author":"Ruet","year":"2014","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2025.106334_bib0083","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2217\/cer-2020-0267","article-title":"Efficacy classification of modern therapies in multiple sclerosis","volume":"10","author":"Samjoo","year":"2021","journal-title":"J. Comp. Eff. Res."},{"issue":"18","key":"10.1016\/j.msard.2025.106334_bib0084","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/cer-2020-0122","article-title":"Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: A network meta-analysis","volume":"9","author":"Samjoo","year":"2020","journal-title":"J. Comp. Eff. Res."},{"issue":"4","key":"10.1016\/j.msard.2025.106334_bib0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.farma.2023.05.005","article-title":"Disease-modifying treatments for patients with multiple sclerosis in Spain","volume":"47","author":"Santiago Perez","year":"2023","journal-title":"Farm. Hosp."},{"issue":"Pt 7","key":"10.1016\/j.msard.2025.106334_bib0086","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/brain\/awq118","article-title":"The natural history of multiple sclerosis: A geographically based study 10: relapses and long-term disability","volume":"133","author":"Scalfari","year":"2010","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.msard.2025.106334_bib0087","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/ana.24241","article-title":"Spinal cord gray matter atrophy correlates with multiple sclerosis disability","volume":"76","author":"Schlaeger","year":"2014","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106334_bib0088","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/WCO.0000000000000937","article-title":"Highly effective disease-modifying treatment as initial MS therapy","volume":"34","author":"Schmierer","year":"2021","journal-title":"Curr. Opin. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106334_bib0089","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","article-title":"Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis","volume":"15","author":"Scolding","year":"2015","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.msard.2025.106334_bib0090","first-page":"875","article-title":"Teriflunomide: A review in relapsing-remitting multiple sclerosis","volume":"79","author":"Scott","year":"2019","journal-title":"Adis. Drug. Eval."},{"issue":"8","key":"10.1016\/j.msard.2025.106334_bib0091","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2025.106334_bib0092","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11940-015-0378-x","article-title":"Acute and chronic management of Neuromyelitis Optica spectrum disorder","volume":"17","author":"Sherman","year":"2015","journal-title":"Curr. Treat. Option. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106334_bib0093","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/1060028017747635","article-title":"Ocrelizumab: a new B-cell therapy for relapsing-remitting and primary progressive multiple sclerosis","volume":"52","author":"Stahnke","year":"2018","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.msard.2025.106334_bib0094","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756285614560733","article-title":"Towards the implementation of \u201cno evidence of disease activity\u201d in multiple sclerosis treatment: the multiple sclerosis decision model","volume":"8","author":"Stangel","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"4","key":"10.1016\/j.msard.2025.106334_bib0095","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2025.106334_bib0096","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","year":"1993","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2025.106334_bib0097","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/1352458516634872","article-title":"Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry","volume":"22","author":"Thiel","year":"2016","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2025.106334_bib0098","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of Multiple Sclerosis: 2017 revisions of the MacDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"21","key":"10.1016\/j.msard.2025.106334_bib0099","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1212\/WNL.0b013e3181feb26f","article-title":"Brainstem lesions in clinically isolated syndromes","volume":"75","author":"Tintore","year":"2010","journal-title":"Neurology"},{"issue":"Pt 7","key":"10.1016\/j.msard.2025.106334_bib0100","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/brain\/awv105","article-title":"Defining high, medium and low impact prognostic factors for developing multiple sclerosis","volume":"138","author":"Tintore","year":"2015","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2025.106334_bib0101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106334_bib0102","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrneurol.2016.188","article-title":"Treatment decisions in multiple sclerosis\u2014Insights from real-world observational studies","volume":"13","author":"Trojano","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2025.106334_bib0103","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101406","article-title":"Expert opinion: criteria for second-line treatment failure in patients with multiple sclerosis","volume":"36","author":"Vermersch","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106334_bib0104","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/ACM.0000000000001092","article-title":"Is there a consensus on consensus methodology? Descriptions and recommendations for future consensus research","volume":"91","author":"Waggoner","year":"2016","journal-title":"Acad. Med."},{"issue":"48","key":"10.1016\/j.msard.2025.106334_bib0105","doi-asserted-by":"crossref","first-page":"e13100","DOI":"10.1097\/MD.0000000000013100","article-title":"A multi-facet comparative analysis of neuromyelitis optica spectrum disorders in patients with seropositive and seronegative AQP4-IgG","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine"},{"issue":"8","key":"10.1016\/j.msard.2025.106334_bib0106","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"2021 MAGNIMS\u2013CMSC\u2013NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"Wattjes","year":"2021","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.msard.2025.106334_bib0107","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrneurol.2015.157","article-title":"MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis\u2014Establishing disease prognosis and monitoring patients","volume":"11","author":"Wattjes","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2025.106334_bib0108","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211039648","article-title":"Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)","volume":"14","author":"Wiendl","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500077X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500077X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T04:49:21Z","timestamp":1741841361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482500077X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":109,"alternative-id":["S221103482500077X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106334","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Central American and Caribbean consensus for the treatment of MS, NMOSD, and MOGAD","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106334"}}